Biological Effects of Anti-ErbB2 Single Chain Antibodies Selected for Internalizing Function
- 12 January 2001
- journal article
- Published by Elsevier BV in Biochemical and Biophysical Research Communications
- Vol. 280 (1), 274-279
- https://doi.org/10.1006/bbrc.2000.4104
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Selection of tumor-specific internalizing human antibodies from phage librariesJournal of Molecular Biology, 2000
- NEW EMBO MEMBERS' REVIEW: The ErbB signaling network: receptor heterodimerization in development and cancerThe EMBO Journal, 2000
- Emerging Antibody-Based HER2 (ErbB-2/neu) TherapeuticsBreast Disease, 2000
- Effects of oncogenic ErbB2 on G1 cell cycle regulators in breast tumour cellsOncogene, 2000
- Toward Selection of Internalizing Antibodies from Phage LibrariesBiochemical and Biophysical Research Communications, 1999
- Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neuBritish Journal of Cancer, 1998
- A subclass of tumor-inhibitory monoclonal antibodies to ErbB-2/HER2 blocks crosstalk with growth factor receptorsOncogene, 1997
- ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signalingThe EMBO Journal, 1997
- In vitro and in vivo characterization of a human anti-c-erbB-2 single-chain Fv isolated from a filamentous phage antibody libraryImmunotechnology, 1995
- Monoclonal antibodies directed to the erbB-2 receptor inhibit in vivo tumour cell growthBritish Journal of Cancer, 1993